Board of Directors

David Ting, MD is the Scientific Co-Founder of PanTher Therapeutics.

As a physician-scientist, cancer biologist, and bioengineer, David is currently Associate Clinical Director for Innovation, Co-Director Biomarker Discovery Lab, and a gastrointestinal oncologist at the Massachusetts General Hospital Cancer Center. He is also currently Associate Professor of Medicine at Harvard Medical School.

Prior to PanTher Therapeutics, David performed biomedical research under Dr. Robert Langer working on DNA vaccine delivery systems, and then a Howard Hughes Medical Institute fellowship at the Whitehead Institute at MIT working on stem cell biology with Dr. George Daley. David also co-founded TellBio, Inc. and ROME Therapeutics.

David holds an MD from Harvard Medical School from the Harvard-MIT Health Sciences and Technology program and a BS in both Chemical Engineering and Biology from MIT.

Laura Indolfi, PhD is the Chief Executive Officer and Co-Founder of PanTher Therapeutics. Laura combines science and business knowledge to drive PanTher’s vision. Prior to founding PanTher Therapeutics, she was a postdoctoral associate at the Harvard-MIT Institute for Medical Engineering and Science and served as an entrepreneur-in-residence at the Massachusetts General Hospital Cancer Center.

Laura’s broad professional experience and interests range from biomedical engineering to entrepreneurship and outreach initiatives to promoting science. Her scientific expertise covers multiple therapeutic areas (cardio, cancer, inflammation, regenerative medicine) and approaches (drug delivery, cell therapy, implanted devices). Together with her strong technical background, Laura has hands-on business and managerial know-how developed during her biomedical business training at Sloan and Harvard Business Schools and with several consulting firms.

She was named a TED Fellow, one of 21 people chosen annually by the TED organization who are considered the most disruptive and transformative change-makers in the world. Laura has also attended the prestigious conference “Fortune: Most Powerful Women – Next Gen”, an invite-only summit hosted by Fortune gathering a stellar group of game-changing entrepreneurs, executives, and innovators in business. Laura is also one of the five women selected by Massachusetts Life Science Center and Takeda for their inaugural class in 2018 of the MassNextGen program, honoring exceptional leaders in the biotech industry.

Laura holds a PhD in Biomaterials and MS and BS degrees in Materials Science and Engineering from the University of Naples Federico II in Italy.